Financhill
Back

CytoMed Therapeutics Stock Predictions

CytoMed Therapeutics Stock Forecast

  • Is CytoMed Therapeutics Stock Undervalued?
    The current CytoMed Therapeutics [GDTC] share price is $2.17. The Score for GDTC is 50, which is 0% below its historic median score of 50, and infers higher risk than normal.
  • GDTC is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.

Will CytoMed Therapeutics Stock Go Up Next Year?

Data Unavailable

CytoMed Therapeutics Stock Rating

Data Unavailable

CytoMed Therapeutics Stock Price History

Is GDTC stock going to rise?

  • Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and GDTC is experiencing slight selling pressure.

Stock Information

Stock Info

Exchange:
NASDAQ
Country:
Singapore
Industry:
Biotechnology
Sector:
Health Care
Type:
stock
Website:
w2.cytomed.sg

52-Week Data

52-Week High:
5.50
52-Week Low:
1.20

Prediction Charts

Market Cap:
25.09M
Price in USD:
2.17
Volume:
10.78K
Beta:
-0.09

Technical Analysis

SMA50:
2.01
SMA100:
1.92
SMA200:
2.05
52-Wk Change:
-45.78%

Stock Predictions

  • Is CytoMed Therapeutics stock public?
    Yes, CytoMed Therapeutics is a publicly traded company.
  • What is the CytoMed Therapeutics stock quote today?
    The CytoMed Therapeutics stock price is 2.17 USD today.
  • How to buy CytoMed Therapeutics stock online?
    You can buy CytoMed Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

14-Day Historical Data

Date Opening Closing Minimum Maximum
Oct-29 2.47 2.34 2.50 2.13
Oct-30 2.21 2.23 2.30 2.15
Oct-31 2.45 2.41 2.45 2.27
Nov-1 2.45 2.31 2.45 2.28
Nov-4 2.26 2.48 2.58 2.25
Nov-5 2.61 2.62 2.83 2.41
Nov-6 2.44 2.44 2.49 2.36
Nov-7 2.29 2.54 2.59 2.24
Nov-8 2.15 2.31 2.55 2.14
Nov-11 2.11 2.39 2.69 2.11
Nov-12 2.31 2.27 2.31 2.18
Nov-13 2.40 2.22 2.60 2.15
Nov-14 2.37 2.12 2.40 2.12
Nov-15 2.20 2.17 2.52 1.83

CytoMed Therapeutics Earnings

Data Unavailable

CytoMed Therapeutics Forecast Revenue Growth

Data Unavailable

  • Analysts estimate an earnings increase this quarter of $0.00 per share, a decrease next quarter of $0.00 per share, an increase this year of $0.11 per share, and a decrease next year of $0.02 per share.

* CytoMed Therapeutics stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.